Public consultation (ARM 61): Request to reclassify domperidone 10mg tablets (Motilium 10) from prescription only medicine (POM) to pharmacy availability (P)

Consultation ARM 61 sought your views on the reclassification from POM to P of domperidone 10 mg tablets (Motilium 10) for the additional indications of nausea and vomiting of less than 48 hours duration.

A total of 13 responses to the consultation were received, of which eight were in favour and five had no comment.

Pharmacy availability of domperidone for the treatment of nausea and vomiting of less than 48 hours duration supports self-care. Pharmacies are conveniently located and have more flexible opening hours, including at weekends.

Organisations supporting the reclassification
These included:

• medical colleges – Royal College of Physicians of Edinburgh
• pharmacy organisations – Royal Pharmaceutical Society of Great Britain (RPSGB)

Organisations not supporting the reclassification
None

Copies of the responses (excluding those marked as 'in confidence') are available below.
The following table summarises how pharmaceutical bodies, medical bodies and others responded to the consultation.

Professional pharmaceutical societies, individual pharmacists, prescribing advisers and other pharmaceutical bodies
Yes to proposal Paediatric Chief Pharmacists Group (1) (30Kb) Individual pharmacist (4) (71Kb) Chief Pharmaceutical Officer (Scotland) (5) (22Kb) Royal Pharmaceutical Society of Great Britain (RPSGB) (8) (85Kb)
No comment Individual pharmacist (13) (30Kb)

Medical profession and royal colleges
Yes to proposal Royal College of Physicians of Edinburgh (2) (51Kb)
No comment Association of Medical Microbiologists (9) (23Kb) British Society for Antimicrobial Chemotherapy (10) (27Kb) British Association of Dermatologists (11) (23Kb) British Society of Gastroenterology (12) (25Kb)

Industry and trade associations
Yes to proposal Independent Healthcare Advisory Services (IHAS) (3) (76Kb)

Others
Yes to proposal Individual (6) (35Kb) Individual (7) (46Kb)